You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Niravam Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Niravam patents expire, and what generic alternatives are available?

Niravam is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in NIRAVAM is alprazolam. There are fifteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the alprazolam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Niravam

A generic version of Niravam was approved as alprazolam by NOVITIUM PHARMA on October 19th, 1993.

  Try a Trial

Drug patent expirations by year for Niravam
Recent Clinical Trials for Niravam

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Actavis Inc.Phase 1
UCB PharmaPhase 4

See all Niravam clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for Niravam
Paragraph IV (Patent) Challenges for NIRAVAM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NIRAVAM Orally Disintegrating Tablets alprazolam 0.25 mg, 0.5 mg, 1 mg and 2 mg 021726 1 2005-12-27

US Patents and Regulatory Information for Niravam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-001 Jan 19, 2005 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-004 Jan 19, 2005 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-002 Jan 19, 2005 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-003 Jan 19, 2005 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Niravam

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-001 Jan 19, 2005 ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-003 Jan 19, 2005 ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-004 Jan 19, 2005 ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-001 Jan 19, 2005 ⤷  Try a Trial ⤷  Try a Trial
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-003 Jan 19, 2005 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for Niravam

See the table below for patents covering Niravam around the world.

Country Patent Number Title Estimated Expiration
Japan 5072513 ⤷  Try a Trial
Denmark 2266538 ⤷  Try a Trial
Portugal 2147669 ⤷  Try a Trial
Canada 2284663 DISSOLUTION RAPIDE DE FORME POSOLOGIQUE DE BONNE TENUE (RAPIDLY DISSOLVING ROBUST DOSAGE FORM) ⤷  Try a Trial
Australia 726336 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.